COVID-19 Risk in Patients With HIV: Implications for ART Management
  • CME

The DHHS released interim guidance on special considerations during the COVID-19 pandemic for patients with HIV. Here’s my take on how these can be incorporated into practice to minimize patient risk.
Paul E. Sax, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Released: April 10, 2020 Expiration: April 9, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply guidance on patient management strategies to reduce the risk of COVID-19 exposure and infection in persons with HIV

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by:
Theratechnologies Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Paul E. Sax, MD

Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Paul E. Sax, MD, has disclosed that he has served as a consultant or on a scientific advisory board for Gilead Sciences, GlaxoSmithKline/ViiV, Janssen, and Merck and has received funds for research support from Gilead Sciences and GlaxoSmithKline/ViiV.

Staff

Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.
Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer Blanchette, PhD, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Tiffany Hensley-McBain, PhD

Clinical Editor

Tiffany Hensley-McBain, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with HIV infection.

Goal

The goal of this activity is to improve awareness of management considerations related to the COVID-19 pandemic for clinicians providing care for persons with HIV infection.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 10, 2020, through April 09, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Expert discussion of data from CROI 2020 on new and established treatment of HIV from Drs. Roger Bedimo and Joseph Eron, provided by CCO

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Roger Bedimo, MD, MS, FACP Daniel R. Kuritzkes, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: May 12, 2020 Expired: May 11, 2021

CCO commentary from Jordan E. Lake, MD, MSc, on the risk of weight gain with ART and what data are needed to inform management of weight gain with ART

Jordan E. Lake, MD, MSc Released: April 27, 2020

Download free expert-authored slides reviewing ART management recommendations for specific patient populations and key data on safety and tolerability

Kristine Erlandson, MD Rajesh T. Gandhi, MD Released: April 24, 2020

Watch this video module from CCO to learn key strategies for individualizing ART management based on regimen safety and tolerability considerations

Kristine Erlandson, MD Rajesh T. Gandhi, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: April 24, 2020 Expired: April 23, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?